内分泌学とメタボリックシンドローム
オープンアクセス

概要

Organoids and diabetes: The changing landscape of laboratory medicine

Sikandar Hayat Khan

Diabetes, undeniably pivots around most of the major killers on our planet, regardless of it's direct impact on atherosclerotic cardiovascular diseases (ASCVD). Though conventional diagnostic & therapeutic approaches are continuously evolving and improving, still these aspects remain handicapped due to limited prognostic nature and being least informative about pharmacogenomics. With diabetic population now surpassing most counts, there is an emerging need to not only developing newer tools of diagnosis & modalities for curative therapeutics. Recent emergence of these 3-D cell culture, commonly termed as “Organoids” provides in many ways a human organ like environment which have been over last decade or so been widely used for various in vitro testing for disease modelling and therapeutic drug evaluation. Organoids, while being useful addition to learning personalized pathogenesis in various diseases can also be useful in diabetes by exploring the specific genetic defects using newer biotechnologies. Furthermore, the journey from diagnostic models to human organ donations is also reaching closer to proof of concept, which will redefine the science organ donation not only in terms of demand and supply issues, but also being safer in terms of various donor recipient rejection and avoidance of immunosuppressive medications. Utilizing the concept of organoids in diagnostics hopefully will allow evaluation of exact of molecular pathogenesis by multiplexing molecular techniques like polymerase chain reactions or newly emerging CRISPR /Cas technologies along with prior assessment of best fit medication for diabetes as per the identified pathogenesis.